Steve Kaldor joins Syrrx as chief scientific officer. He comes from Eli Lilly, where he had 12 years of drug discovery and development experience.
Exelixis appoints Robert Myers, formerly of ALZA, to the position of executive vice president of pharmaceuticals.
Ira Marks comes aboard at Nanogen as VP of business development. Marks, who’s charged with maintaining a company emphasis on molecular diagnostics, comes from Hemagen Diagnostics, where he was president of the Raichem division.
Former Amersham CEO Ron Long moves to The Automation Partnership as deputy chairman to guide the company toward the life sciences industry.
Pui-Yan Kwok, a geneticist at Washington University, will collaborate with Massachusetts-based US Genomics, using the company’s technology in his lab and to develop new technology for the platform.
John Baldwin, chief science and technology officer at Pharmacopeia, announced plans to retire at the end of last month. Now 67, Baldwin was the first employee of the company when it was founded in 1993.
Structural biology company Astex Technology appoints former Roche scientist Glyn Williams as director of biophysics.
Frank Reeves, chief financial officer at Luminex, has left. The Texas-based company is looking for a replacement with more accounting experience at public firms.
Oxford GlycoSciences recently named Don DeGolyer president of global therapeutics. DeGolyer previously spent 16 years with Pfizer and Johnson & Johnson.
ProSanos announces that Bettina Steffen, previously vice president of business development at InterMap Systems, joins as vice president for market development.
Max Perutz, a Nobel laureate remembered for his significant contributions to the field of molecular biology and protein structure — notably, defining the structure of hemoglobin — died of cancer at 87 in Cambridge, UK.
Months after Cray CEO and president James Rottsolk stepped aside to make room for Michael Haydock, the company announced that Haydock’s heading out and Rottsolk’s stepping back in. It just wouldn’t be any fun if we knew what was coming.
On the other hand, we do love to say we told you so. Back in August, GT wondered how Peter Nicholson would fare as CEO of Blue Heron Biotechnology, funded by Leroy Hood and David Galas. Our answer came with a recent press release announcing Nicholson’s appointment as VP of investor relations and corporate communications at Inamed. Better luck this time, Pete.